A suPAR biomarker for chronic kidney disease

Karl L. Skorecki, Barry I. Freedman

Research output: Contribution to journalEditorial

10 Scopus citations

Abstract

The worldwide epidemic of chronic kidney disease — an insidious illness that manifests with asymptomatic reductions in the estimated glomerular filtration rate (eGFR) to less than 60 ml per minute per 1.73 m2 of body-surface area, excessive urinary excretion of protein, or both — afflicts an estimated 600 million people.1 Many will have progression to end-stage kidney disease and require dialysis or kidney transplantation for survival or succumb to related cardiovascular complications, even while taking antihypertensive agents and medications to lower blood glucose levels.2,3 Chronic kidney disease shortens survival, reduces the quality of life remaining to these patients, and . . .
Original languageEnglish
Pages (from-to)1971-1972
Number of pages2
JournalNew England Journal of Medicine
Volume373
Issue number20
DOIs
StatePublished - 12 Nov 2015
Externally publishedYes

Fingerprint

Dive into the research topics of 'A suPAR biomarker for chronic kidney disease'. Together they form a unique fingerprint.

Cite this